One of the biggest headlines of recent days has been the announcement made by Pfizer, a U.S.-based company, and BioNTech, Germany, that BNT162b2, a COVID-19 vaccine they are developing, has proved to be 90% effective in its Phase 3 clinical trial. The news was met with big excitement all over the world. However, the Pfizer-BioNTech vaccine is based on a new platform, which is still understudied. According to protocol, its trial will be complete only in 2022. IQ talked to Larisa Popovich, Director of the HSE Institute for Health Economics, about the differences between the U.S.-German and the Russian Sputnik V vaccines, and about the chances of beating COVID-19 with massive immunization in the upcoming months.